1. Home
  2. ITRM vs LEO Comparison

ITRM vs LEO Comparison

Compare ITRM & LEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ITRM
  • LEO
  • Stock Information
  • Founded
  • ITRM 2015
  • LEO 1987
  • Country
  • ITRM Ireland
  • LEO United States
  • Employees
  • ITRM N/A
  • LEO N/A
  • Industry
  • ITRM Biotechnology: Pharmaceutical Preparations
  • LEO Trusts Except Educational Religious and Charitable
  • Sector
  • ITRM Health Care
  • LEO Finance
  • Exchange
  • ITRM Nasdaq
  • LEO Nasdaq
  • Market Cap
  • ITRM 35.6M
  • LEO N/A
  • IPO Year
  • ITRM 2018
  • LEO N/A
  • Fundamental
  • Price
  • ITRM $1.02
  • LEO $5.95
  • Analyst Decision
  • ITRM Strong Buy
  • LEO
  • Analyst Count
  • ITRM 2
  • LEO 0
  • Target Price
  • ITRM $7.00
  • LEO N/A
  • AVG Volume (30 Days)
  • ITRM 571.6K
  • LEO 200.2K
  • Earning Date
  • ITRM 05-13-2025
  • LEO 01-01-0001
  • Dividend Yield
  • ITRM N/A
  • LEO 4.01%
  • EPS Growth
  • ITRM N/A
  • LEO N/A
  • EPS
  • ITRM N/A
  • LEO 0.04
  • Revenue
  • ITRM N/A
  • LEO N/A
  • Revenue This Year
  • ITRM N/A
  • LEO N/A
  • Revenue Next Year
  • ITRM $108.39
  • LEO N/A
  • P/E Ratio
  • ITRM N/A
  • LEO $152.00
  • Revenue Growth
  • ITRM N/A
  • LEO N/A
  • 52 Week Low
  • ITRM $0.81
  • LEO $4.98
  • 52 Week High
  • ITRM $3.02
  • LEO $6.50
  • Technical
  • Relative Strength Index (RSI)
  • ITRM 44.07
  • LEO 53.20
  • Support Level
  • ITRM $0.88
  • LEO $5.79
  • Resistance Level
  • ITRM $1.14
  • LEO $5.95
  • Average True Range (ATR)
  • ITRM 0.10
  • LEO 0.07
  • MACD
  • ITRM -0.01
  • LEO 0.03
  • Stochastic Oscillator
  • ITRM 30.56
  • LEO 94.64

About ITRM Iterum Therapeutics plc

Iterum Therapeutics PLC is a pharmaceutical company dedicated to maximizing the commercial potential of Orlynvah, an oral-branded penem available in the United States and potentially the first and only oral and intravenous (IV) branded penem available globally. Its product Orlynvah has the potential to be a treatment for complicated urinary tract infections caused by the designated microorganisms, without the presence of known toxicities of some other antibiotics. The company operates in a single business segment, which is the development and commercialization of treatments for drug-resistant bacterial infections.

Share on Social Networks: